CXCL14 通过调节肿瘤细胞侵袭和免疫微环境抑制结肠癌进展

CXCL14 is a highly conserved chemokine with potential roles in tumor progression and immune modulation.

This study investigates the functional impact of CXCL14 on colon cancer by exploring its effects on tumor cell behavior and the immune microenvironment.

We generated stable cell lines overexpressing CXCL14 in mouse MC38 and CT26 cells and human HCT15 colon cancer cells, and used these models to assess tumor growth, invasion, and immune cell infiltration.

Our results demonstrate that CXCL14 suppresses colon cancer cell proliferation, migration, and metastasis. In vitro, CXCL14 inhibited the expression of matrix metalloproteinases (MMPs), key regulators of epithelial-mesenchymal transition (EMT), suggesting a role in promoting mesenchymal-epithelial transition (MET).

Additionally, in vivo studies using a subcutaneous tumor model showed that CXCL14 not only suppressed tumor growth but also enhanced the infiltration of immune cells, including NK cells, dendritic cells (DCs), and T cells, converting the tumor microenvironment from a "cold" to a "hot" phenotype. RNA sequencing and pathway analyses revealed that CXCL14 regulates the expression of genes associated with angiogenesis, immune response, and cell signaling, particularly through the MAPK pathway.

Furthermore, CXCL14's influence on tumor progression was confirmed in a spleen-to-liver metastasis model, where its overexpression reduced metastatic spread.

In conclusion, CXCL14 inhibits colon cancer progression by modulating both tumor cell behavior and the immune landscape, making it a promising candidate for targeted immunotherapy.

Our findings highlight CXCL14's potential to enhance anti-tumor immunity and provide new insights into its therapeutic applications in colon cancer.